Search

Author/Creator Portman, Daneal

2. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Issue 12 (December 2021)

Authors:
Soumerai, Jacob D; Mato, Anthony R; Dogan, Ahmet; Seshan, Venkatraman E; Joffe, Erel; Flaherty, Kelsey; Carter, Jason; Hochberg, Ephraim; Barnes, Jeffrey A; Hamilton, Audrey M; Abramson, Jeremy S; Batlevi, Connie L; Matasar, Matthew J; Noy, Ariela; Owens, Colette N; Palomba, M Lia; Kumar, Anita; ...
Journal:
Lancet
Issue:
Volume 8:Issue 12(2021)
Page Start:
e879
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search